TrialDiabetes & metabolism journal2021
A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus.
Sae Jeong Yang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.